At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
E7777drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating E7777 for Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma. Completed, enrolled 45 participants across 20 sites.
Detailed Summary
The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2016
Primary CompletionApr 2019
TodayJul 2026
First PostedFeb 8, 2016
Enrollment StartMar 28, 2016
Primary CompletionApr 26, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.4 years ago
Interventions
E7777drug